Skip to main content
OpenTrials

Clinical trial condition

Refractory Follicular Lymphoma

Explore clinical trials studying Refractory Follicular Lymphoma. Study availability and eligibility vary by location and protocol.

35 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Refractory Follicular Lymphoma trial results

Completed

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

NCT02568553

Conditions
Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +53 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View all 24 locations
View Trial Details
Completed

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

NCT02956382

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Georgetown Lombardi Comprehensive Cancer Center Washington D.C., District of Columbia, United States
  • John Theurer Cancer Center at Hackensack University Medical Center Hackensack, New Jersey, United States
  • Seattle Cancer Care Alliance Seattle, Washington, United States
View Trial Details
Completed

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

NCT02869633

Conditions
Blastoid Variant Mantle Cell Lymphoma, Chronic Disease, Disease Attributes, +27 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Stanford Cancer Institute Palo Alto, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
View Trial Details

Related conditions